552-98-7

552-98-7 structure

Name: lithium O-acetylsalicylate
Chemical Name: lithium,2-acetyloxybenzoate
CAS Number: 552-98-7
Molecular Formula: C₉H₇LiO₄
Molecular Weight: 186.09000
Catalog: Signaling Pathways Apoptosis Apoptosis
Create Date: 2016-05-11 15:54:32
Modify Date: 2024-01-12 08:14:36
Aspirin (Acetylsalicylic Acid) lithium is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin lithium induces apoptosis. Aspirin lithium inhibits the activation of NF-κB. Aspirin lithium also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis[1][2][3][4][5][6].

Name	lithium,2-acetyloxybenzoate
Synonyms	lithium 2-acetoxybenzoate EINECS 209-029-5 lithium O-acetylsalicylate Lithium acetylsalicylate 2-acetoxy-benzoic acid,lithium-salt 2-Acetoxy-benzoesaeure,Lithium-Verbindung 2-Acetoxy-benzoesaeure,Lithium-Salz

Description	Aspirin (Acetylsalicylic Acid) lithium is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin lithium induces apoptosis. Aspirin lithium inhibits the activation of NF-κB. Aspirin lithium also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis[1][2][3][4][5][6].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer Research Areas >> Cardiovascular Disease Research Areas >> Infection Signaling Pathways >> Autophagy >> Autophagy Signaling Pathways >> Apoptosis >> Caspase Signaling Pathways >> MAPK/ERK Pathway >> p38 MAPK Research Areas >> Inflammation/Immunology Signaling Pathways >> Immunology/Inflammation >> COX Signaling Pathways >> Autophagy >> Mitophagy Research Areas >> Metabolic Disease
Target	COX-1 COX-2
In Vitro	Aspirin lithium inhibits COX-1 and COX-2 in human articular chondrocytes, with IC50 values of 3.57 μM and 29.3 μM, respectively[2]. Aspirin lithium acetylates serine-530 of COX-1, thereby blocking thromboxane A synthesis in platelets and reducing platelet aggregation[3]. Aspirin lithium inhibits COX-2 protein expression through interference with binding of CCAAT/enhancer binding protein beta (C/EBPbeta) to its cognate site on COX-2 promoter/enhancer[3]. Aspirin lithium inhibits NF-κB-dependent transcription from the lgκ enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells[4]. Aspirin lithium induces apoptosis by the activation of caspases, the activation of p38 MAP kinase, release of mitochondrial cytochrome c, and activation of the ceramide pathway[6].
In Vivo	Aspirin lithium (5-150 mg/kg, PO, once) shows significant antipyretic activity in adult yeast-fevered male rats[7]. Animal Model: Male albino Charles River rats (200-250 g, 8 animals/group, fever was induced by 20 ml/kg of a 20 % aqueous suspension of brewer’s yeast which was injected SC in the back below the nape of the neck)[7] Dosage: 5, 25, 50, 100 and 150 mg/kg Administration: PO, once Result: Produced a statistically significant decrease of 0.23 ℃ at 15 min post-drug at the dose of 150 mg/kg. Antipyretic effect gradually increased in magnitude until a peak effect of 1.96 ℃ was reached at 120 min post-drug. The ED50 of aspirin was found to be 10.3 mg/kg with confidence limits of 1.8-23.0 mg/kg. The antipyretic response to aspirin is dependent on the dose of the compound administered.
References	[1]. Mitchell JA, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and induciblecyclooxygenase. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11693-7. [2]. Blanco FJ, et al. Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999 Jun;26(6):1366-73. [3]. Wu KK, et al. Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med. 2003 May;3(2):107-12. [4]. Kopp E, et al. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994 Aug 12;265(5174):956-9. [5]. Burch JW, et al. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest. 1978 Feb;61(2):314-9. [6]. Elwood PC, et al. Aspirin, salicylates, and cancer. Lancet. 2009 Apr 11;373(9671):1301-9. [7]. Loux JJ, DePalma PD, Yankell SL. Antipyretic testing of aspirin in rats. Toxicol Appl Pharmacol. 1972 Aug;22(4):672-5.

Boiling Point	321.4ºC at 760mmHg
Molecular Formula	C₉H₇LiO₄
Molecular Weight	186.09000
Flash Point	131.2ºC
Exact Mass	186.05000
PSA	66.43000

HS Code	2918229000

50-78-2

552-98-7

Literature: Gerngross; Kersasp Justus Liebigs Annalen der Chemie, 1914 , vol. 406, p. 252

HS Code	2918229000
Summary	2918229000. other o-acetylsalicylic acid salts and esters. VAT:17.0%. Tax rebate rate:9.0%. . MFN tariff:6.5%. General tariff:30.0%

552-98-7	57901-57-2
132-49-0	493-53-8
70875-96-6	529-68-0
6699-93-0	94159-26-9
94108-12-0	69705-27-7
1158522-08-7	1038233-99-6
1100762-61-5	940364-43-2
921996-88-5	134104-43-1
131615-57-1	6906-52-1
1096301-04-0	922078-26-0